1394929-55-5

Basic information

• Product Name: (E)-N,N-DidesMethyl-4-hydroxy TaMoxifen
• Synonyms: (E)-N,N-DidesMethyl-4-hydroxy TaMoxifen;(E)-4-[1-[4-(2-AMinoethoxy)phenyl]-2-phenyl-1-buten-1-yl]phenol
• CAS NO: 1394929-55-5
• Molecular Formula: C₂₄H₂₅NO₂
• Molecular Weight: 359.4608
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 1394929-55-5.mol
• Article Data: 2

Chemical Properties

• Melting Point: 204-206°C
• Appearance: /
• Storage Temp.: Amber Vial, -20?C Freezer, Under Inert Atmosphere
• Solubility: Methanol (Sparingly, Heated)
• CAS DataBase Reference: (E)-N,N-DidesMethyl-4-hydroxy TaMoxifen(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-N,N-DidesMethyl-4-hydroxy TaMoxifen(1394929-55-5)
• EPA Substance Registry System: (E)-N,N-DidesMethyl-4-hydroxy TaMoxifen(1394929-55-5)

Safety Data

• Hazardous Substances Data: 1394929-55-5(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Upstream product

• 93-55-0 1-phenyl-propan-1-one 
• 114031-67-3 [4-(4-hydroxybenzoyl)phenyl]-2,2-dimethyl propanoate 
• 177748-17-3 (E)-1-(4-hydroxyphenyl)-1-[4-(trimethylacetoxy)phenyl]-2-phenylbut-1-ene 
• 1440533-06-1 (E)-4-(1-(4-(2-amino-2-oxoethoxy)phenyl)-2-phenylbut-1-enyl)phenyl Pivalate 
• 93-54-9 1-Phenyl-1-propanol 
• 611-99-4 4,4'-Dihydroxybenzophenone 
• 1217237-98-3 4-(1-(4-(2-aminoethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol 

Relevant articles and documents

Rational design of ERα targeting hypoxia turn-on fluorescent probes with antiproliferative activity for breast cancer

The overexpression of estrogen receptor (ER) α is not only closely related to the development of ER+ breast cancer, but is also an important biomarker for clinical diagnosis and treatment. Herein, we report several ERα targeting hypoxia turn-on fluorescent probes with antitumor activity for breast cancer cells. Among them, probes 3 and 5 displayed good ERα targeting ability and favorable hypoxia turn-on response in MCF-7 cells. Moreover, the probes 3 and 5 exhibited good antiproliferative activity towards MCF-7 cells (IC50 = 8.5 μM, 10.3 μM) and a much lower cytotoxicity to normal cells compared with the positive control. It is expected that these novel fluorescent probes may provide useful tools for the theranostics of ER+ breast cancer.